Simplex Trading
ABCL icon

Simplex Trading’s AbCellera Biologics ABCL Stock Holding History

Simplex Trading’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.05M Sell
300,500
-35,600
-11% -$128K ﹤0.01% 2450
2025
Q4 		$1.15M Buy
336,100
+17,400
+5% +$77.7K ﹤0.01% 2499
2025
Q3 		$1.6M Sell
318,700
-96,100
-23% -$424K ﹤0.01% 2547
2025
Q2 		$1.42M Buy
414,800
+317,200
+325% +$790K ﹤0.01% 2426
2025
Q1 		$217K Buy
97,600
+32,300
+49% +$92.6K ﹤0.01% 4231
2024
Q4 		$191K Buy
65,300
+57,400
+727% +$160K ﹤0.01% 4559
2024
Q3 		$20K Buy
7,900
+3,200
+68% +$8.87K ﹤0.01% 6656
2024
Q2 		$13K Sell
4,700
-1,000
-18% -$3.78K ﹤0.01% 7219
2024
Q1 		$25K Sell
5,700
-101,000
-95% -$515K ﹤0.01% 6894
2023
Q4 		$609K Sell
106,700
-17,500
-14% -$81.1K ﹤0.01% 3491
2023
Q3 		$571K Buy
124,200
+38,400
+45% +$234K ﹤0.01% 3252
2023
Q2 		$554K Sell
85,800
-27,200
-24% -$186K ﹤0.01% 3201
2023
Q1 		$852K Sell
113,000
-24,200
-18% -$220K ﹤0.01% 2735
2022
Q4 		$1.39M Sell
137,200
-8,100
-6% -$93.6K ﹤0.01% 2160
2022
Q3 		$1.44M Buy
145,300
+102,000
+236% +$1.12M ﹤0.01% 2277
2022
Q2 		$461K Sell
43,300
-11,100
-20% -$94K ﹤0.01% 3526
2022
Q1 		$530K Sell
54,400
-300
-0.5% -$2.84K ﹤0.01% 3771
2021
Q4 		$782K Buy
54,700
+42,200
+338% +$640K ﹤0.01% 3206
2021
Q3 		$257K Sell
12,500
-3,900
-24% -$68.9K ﹤0.01% 5173
2021
Q2 		$360K Buy
16,400
+16,344
+29,186% +$451K ﹤0.01% 4673
2021
Q1 		$190K Buy
+56
New +$2.23K ﹤0.01% 4816

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Simplex Trading's ABCL Position: Q1 2026 in Review

Simplex Trading opened a new position in AbCellera Biologics (ABCL) in Q1 2026: 201,236 shares worth $702K. The stake represents ﹤0.01% of the portfolio and ranks #2880 among its holdings. This is a return to the name: Simplex Trading previously reported a position in ABCL as recently as Q3 2025.

Simplex Trading first reported a position in ABCL in Q1 2021 and has held it in 18 quarters since. The position peaked at $1.22M in Q4 2021. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Simplex Trading held 201,236 shares of AbCellera Biologics worth $702K as of Q1 2026.
  • AbCellera Biologics was a new Simplex Trading position in Q1 2026.
  • AbCellera Biologics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #2880 holding.
  • Simplex Trading first reported a position in AbCellera Biologics in Q1 2021 and has held it in 18 quarters since.
  • Simplex Trading's AbCellera Biologics position peaked at $1.22M in Q4 2021.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.